GHK-Cu results: what to expect and when
A copper-binding skin peptide with small topical studies and untested systemic injections.
Also called: Copper tripeptide-1, Glycyl-L-histidyl-L-lysine copper, Copper-GHK.
Healing and repair peptides · Copper-binding tripeptide complex.
A diabetic-foot-ulcer trial used GHK-Cu gel daily for up to eight weeks alongside wound care; this does not define an injection course.
17 human records include secondary reports, mixed products, historical phase 3 news and 1 recruiting trial. No verified systemic injection trial was found.
Key studies
- Venous ulcers: no benefit: Copper-peptide cream did no better than vehicle. (source)
- Diabetic ulcers: immediate and delayed gel: Immediate-start gel improved median plantar-ulcer area closure. (source)
- Thigh skin: collagen biopsy pilot: Collagen-marker improvement was seen in 7/10 copper-peptide sites. (source)
- Makeup formulations: conference report: The review reports improved skin ratings with both formulations. (source)
- Facial cream: 71 women: Reviews report better skin appearance than control. (source)
- Eye cream: 41 women: Reviews report improvement versus vehicle and vitamin K cream. (source)
Related to GHK-Cu
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
- TB-500: A short piece of thymosin beta-4 with no proven repair benefit in humans.
- AHK-Cu: A copper peptide used in scalp serums, with laboratory findings and weak patent-only human data.
- Thymosin beta-4: A peptide studied for eye conditions and skin wounds; tendon-repair injections lack controlled human evidence.
- ARA-290: Experimental peptide studied for small-fiber nerve damage, with uncertain pain relief and safety.
- Ac-SDKP: An experimental repair peptide with old human studies, but no proven healing dose.
Sources
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Concerns regarding the public health risks associated with unapproved peptide products, Therapeutic Goods Administration and Chief Medical Officer · Therapeutic Goods Administration · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- WEGOVY- semaglutide injection, solution WEGOVY- semaglutide tablet, DailyMed · DailyMed · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Diabetic foot problems: prevention and management, NICE · 2015
- Biotechnology Inspection Guide (11/91), FDA · 1991
- Copper - Health Professional Fact Sheet, NIH Office of Dietary Supplements
- Treatment of Wilson Disease, NIDDK · NIDDK
- Augmented Skin Beneficial Effects of Thermus Thermophilus and Bacillus Subtilis Mixed-Culture Ferment Extract by Tripeptide GHK-Cu., Wang J et al. · Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2026
- THE EFFICACY OF 2% COPPER PEPTIDE (GHK-Cu) SERUM FOR EYEBROW HYPOTRICHOSIS: A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, SPLIT-FACE COMPARATIVE STUDY, Bo SL et al. · Procedia of Multidisciplinary Research · 2026
- The Regenerative Potential of GHK-Cu in Aesthetic Medicine., Mokhtar J et al. · Aesthetic surgery journal · 2026
- A study comparing the effect of dermaroller versus dermaroller with copper peptide in the management of acne scars, 2025
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.